Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.

Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.

One of the major challenges in treatment of chronic myeloid leukemia (CML) is the continual emergence of new resistance to single agent Bcr-Abl tyrosine kinase inhibitors (TKIs). A strategy to cope with cancer progression is by targeting multiple levels of signaling pathways downstream of B...

Saved in:

書目詳細資料
主要作者:	Koh, Yanqing.
其他作者:	School of Biological Sciences
格式:	Final Year Project
語言:	English
出版:	2011
主題:	DRNTU::Science::Biological sciences::Biochemistry
在線閱讀:	http://hdl.handle.net/10356/45121
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Nanyang Technological University
語言:	English

相似書籍

Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population
由: Budi Suprapti, et al.
出版: (2020)

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
由: Sung Hyun Kim, et al.
出版: (2018)

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients
由: Wanwisa Wongboonma, et al.
出版: (2018)

A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
由: Limsuwanachot N.
出版: (2023)

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
由: Rauzan M., et al.
出版: (2020)

BCR-ABL Tyrosine Kinase Domain Mutations Combinations Affects Imat inib Resistence in Chronic Phase Chronic Myelogenous Leukemia
由: Siprianus Ugroseno Yudho Bintoro, et al.
出版: (2019)

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand
由: Nittaya Limsuwanachot, et al.
出版: (2020)

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
由: Giuseppe Saglio, et al.
出版: (2018)

Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants
由: C. U. Auewarakul, et al.
出版: (2018)

MECHANISMS OF HYPOXIA-INDUCED GROWTH AND TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA
由: MANJERI ADITI SUBRAMANIAM
出版: (2019)

Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571 [4]
由: Chagriya Kitiyakara, et al.
出版: (2018)

The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
由: Zhou J., et al.
出版: (2018)

Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib
由: Ami Ashariati Prayoga, et al.
出版: (2014)

Hubungan Kadar Betha2 Mikroglobulin Serum Terhadap Rasio BCR-ABL Pada Pasien Leukemia Granulositik Kronik (LGK) Dengan Terapi Tyrosin Kinase Inhibitor
由: Budiono Raharjo, NIM011519079301
出版: (2018)

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
由: Nowak, D., et al.
出版: (2016)

Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
由: Thanawat Rattanathammethee, et al.
出版: (2018)

SRSF1-MEDIATED TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKAEMIA
由: SINNAKANNU JOANNA RAJESWARY
出版: (2018)

ROLE OF BREAK CLUSTER REGION (BCR) - ABELSON MURINE LEUKIMIA (ABL) EXAMINATION IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
由: Agung Sosiawan
出版: (2014)

TARGETED COVALENT REVERSIBLE BCR-ABL INHIBITORS
由: DAVID QUACH THANH TRUONG
出版: (2020)

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
由: Kongruang A.
出版: (2023)

Detection of Molecular Variants of BCR-ABL Gene in Bone Marrow and Blood of Patients with Chronic Myeloid Leukemia by Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
由: Chirayu Udomsakdi-Auewarakul, et al.
出版: (2018)

Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand
由: Wantanee Kulpeng, et al.
出版: (2018)

Profile Of BCR-ABL Transcipt Levels Based on Sokal prognostic Score in Chronic Myeloid Leukimia Patients Treated With lmatinib
由: Ugroseno Yudho Bintoro, Siprianus
出版: (2013)

Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
由: Thanawat Rattanathammethee, et al.
出版: (2018)

Chromosomal aberrations and molecular changes in BCR-ABL gene in Chronic Myelogenous Leukemia (CML) patients undergoing chemotherapy
由: Soriano-Abad, Ma. Celeste S.
出版: (2010)

Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
由: Franck E. Nicolini, et al.
出版: (2018)

A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: Diagnostic challenges in clinical laboratory practice
由: Natini Jinawath, et al.
出版: (2018)

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
由: Hagop M. Kantarjian, et al.
出版: (2022)

Detection of bcr-abl Fusion Gene Expression in Chronic Myelogenous
由: Perpustakaan UGM, i-lib
出版: (2004)

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
由: Franck E. Nicolini, et al.
出版: (2018)

IN SILICO STUDY OF IODINATED 5,10,15,20-TETRAKIS(4-AMINOPHENYL) PORPHYRIN AS RADIOPHARMACEUTICALS CANDIDATE FOR CHRONIC MYELOID LEUKEMIA THERAPY AGAINST BCR-ABL1T315I
由: Kurniawan, Michael

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
由: A. Hochhaus, et al.
出版: (2018)

Role of Bruton's tyrosine kinase (Btk) in BCR and TLR signalling
由: LEE KOON GUAN
出版: (2011)

Magnetic Nanoparticles PCR Enzyme-Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia
由: Yanaphat Manthawornsiri, et al.
出版: (2018)

C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion
由: Hayashi, Y., et al.
出版: (2016)

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
由: Nicolini, F.E., et al.
出版: (2016)

Tyrosine kinase c-Abl regulates the survival of plasma cells
由: Li, Y.-F, et al.
出版: (2020)

Gene Mutation Profile in Chronic Myelogenous Leukemia BCR-ABL. Positive Chronic Phase Patients Which not Response to lmatinib Treatment in Dr. Soetomo Teaching Hospital Surabaya lndonesia
由: Ugroseno Yudho Bintoro, Siprianus
出版: (2014)

Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
由: Sung Eun Lee, et al.
出版: (2019)

คู่มือปฏิบัติงานการทดสอบ BCR-ABL gene
由: อรทัย พรหมสุวิชา
出版: (2016)